Journal
The oncologist
Publication Date
11-1-2019
Volume
24
Issue
11
First Page
1497
Last Page
1501
Document Type
Open Access Publication
DOI
10.1634/theoncologist.2019-0316
Rights and Permissions
Daniel J. George, Colin Hessel, Susan Halabi, M. Dror Michaelson, Olwen Hahn, Meghara Walsh, Joel Picus, Eric J. Small, Shaker Dakhil, Darren R. Feldman, Milan Mangeshkar, Christian Scheffold, Michael J. Morris, Toni K. Choueiri, Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial, The Oncologist, Volume 24, Issue 11, November 2019, Pages 1497–1501, doi.org/10.1634/theoncologist.2019-0316 © 2019 The Authors. The Oncologist published by Wiley Periodicals, Inc. on behalf of AlphaMed Press. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reuse, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Recommended Citation
George, Daniel J; Hessel, Colin; Halabi, Susan; Michaelson, M Dror; Hahn, Olwen; Walsh, Meghara; Picus, Joel; Small, Eric J; Dakhil, Shaker; Feldman, Darren R; Mangeshkar, Milan; Scheffold, Christian; Morris, Michael J; and Choueiri, Toni K, "Cabozantinib versus sunitinib for untreated patients with advanced renal cell carcinoma of intermediate or poor risk: Subgroup analysis of the Alliance A031203 CABOSUN trial." The oncologist. 24, 11. 1497 - 1501. (2019).
https://digitalcommons.wustl.edu/open_access_pubs/11894
Supplemental Figures
